Voyager Acquisition Corp Unit

VACHU

Börsenwert 367 Mio. $

ZURICH, Switzerland, and BROOKLYN, New York, April 23, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, “Voyager” or the “SPAC”), announced today that they have entered into a definitive business combination agreement (the "Business Combination Agreement"). The proposed business combination (the "Business Combination") would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol “VERX.”

BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units sold in the Company's initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the exercise by the underwriters of their overallotment option, completed on August 12, 2024 (the “Offering”) may elect to separately trade the Class A ordinary shares and warrants included in the units commencing on or about September 30, 2024. Any units not separated will continue to trade on The Nasdaq Global Market under the symbol “VACHU”, and each of the Class A ordinary shares and warrants will separately trade on The Nasdaq Global Market under the symbols “VACH” and “VACHW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into Class A ordinary shares and warrants.

BROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) today announced that it closed its initial public offering of 25,300,000 units at $10.00 per unit, including the issuance of 3,300,000 units as result of the underwriters' exercise of its over-allotment option in full. The gross proceeds from the offering were $253 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “VACHU” on August 9, 2024.